Study of feasibility of the treatment with procainamide hydrochloride and cisplatin in pregnant mice

Chemico-Biological Interactions

Volumn 164, Issue 3, 2006, Pages 232-240

  Ognio, Emanuela ^a   Chiavarina, Barbara ^b   Peterka, Miroslav ^c   Mariggiò, Maria A ^d   Viale, Maurizio ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c INSTITUTE OF EXPERIMENTAL BOTANY   (Czech Republic)

^d UNIVERSITY OF BARI   (Italy)

Author keywords

Chemoprotection; Cisplatin; Embryotoxicity; Procainamide hydrochloride

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; PROCAINAMIDE; TERATOGENIC AGENT;

ANALYTICAL PARAMETERS; ANIMAL CELL; ANIMAL EMBRYO; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; EMBRYOTOXICITY; EXPERIMENTAL MOUSE; FEASIBILITY STUDY; FETUS (ANATOMY); FETUS DISEASE; FETUS WEIGHT; MOUSE; NONHUMAN; OSSIFICATION; PHARMACOLOGICAL BLOCKING; PLACENTA; PREGNANCY; PROGENY; PROTECTION; RISK ASSESSMENT; SKELETON MALFORMATION; TERATOGENICITY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; EMBRYO; EMBRYO LOSS; FEASIBILITY STUDIES; FEMALE; FETUS; MICE; PLACENTA; PREGNANCY; PROCAINAMIDE;

EID: 33751259085     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2006.10.001     Document Type: Article

References (44)

1. Thigpen T., Vance R., Puneky L., and Khansurt T. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomised trials. Gynecol. Oncol. 55 (1994) 97-607
2. Van Basten J.P., Schrafford-Koops H., Sleijfer D.T., Pras E., van Driel M.F., and Hoekstra H.J. Current concept about testicular cancer. Eur. J. Surg. Oncol. 23 (1997) 354-360
3. Recchia F., Lalli A., Lombardo M., De Filippis S., Saggio G., Fabbri F., Rosselli M., Capomolla E., and Rea S. Ifosfamide, cisplatin, and 13-cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I-II study. Cancer 92 (2001) 814-821
4. Screnci D., and McKeage M.J. Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J. Inorg. Biochem. 77 (1999) 105-110
5. Sweeney C. History of testicular cancer chemotherapy: maximizing efficacy, minimizing toxicity. Semin. Urol. Oncol. 1 (2001) 170-179
6. Lazar R., Conran P.C., and Damjanov I. Embryotoxicity and teratogenicity of cis-diamminedichloroplatinum. Experientia 35 (1979) 647-648
7. Keller K.A., and Aggarwal S.K. Embryotoxicity of cisplatin in rats and mice. Toxicol. Appl. Pharmacol. 69 (1983) 245-256
8. Bajt M.L., and Aggarwal S.K. An analysis of factors responsible for resorption of embryos in cisplatin-treated rats. Toxicol. Appl. Pharmacol. 80 (1985) 97-107
9. Köpf-Maier P., Erkenswick P., and Merker H.J. Lack of severe malformations versus occurrence of marked embryotoxic effects after treatment of pregnant mice with cis-platinum. Toxicology 34 (1985) 321-331
10. Jänne P.A., Rodriguez-Thompson D., Metcalf D.R., Swanson S.J., Greisman H.A., Wilkins-Haug L., and Johnson B.E. Chemotherapy for a patient with advanced non-small-cell lung cancer during pregnancy. Oncology 61 (2001) 174-183
11. Tewari K., Cappuccini F., Gambino A., Kohler M.F., Pecorelli S., and DiSaia P.J. Neoadjuvant chemotherapy in the treatment of locally advanced cervical carcinoma in pregnancy. Cancer 82 (1998) 1529-1534
12. Bohm S., Oriana S., Spatti G., Di Re F., Breasciani G., Pirovano C., Grosso I., Martini C., Caraceni A., Pilotti S., and Zunino F. Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma. Oncology 57 (1999) 115-120
13. Basinger M.A., Jones M.M., and Holscher M.A. l-Methionine antagonism of cis-platinum nephrotoxicity. Toxicol. Appl. Pharmacol. 103 (1990) 1-15
14. Esposito M., Vannozzi M.O., Viale M., Fulco R.A., Collecchi P., Merlo F., De Cian F., Zicca A., Cadoni A., and Poirier M.C. Para-Aminobenzoic acid suppression of cis-diamminedichloroplatinum(II) nephrotoxicity. Carcinogenesis 12 (1993) 2595-2599
15. Hussain A.E., Blakley B.W., Nicolas M., and Balderston J. Assessment of the protective effects of amifostine against cisplatin-induced toxicity. J. Otolaryngol. 32 (2003) 294-297
16. Markman M. Amifostine in reducing cisplatin toxicity. Semin. Oncol. 25 (1998) 522-524
17. Skinner R. Strategies to prevent nephrotoxicity of anticancer drugs. Curr. Opin. Oncol. 7 (1995) 310-315
18. Esposito M., Viale M., Vannozzi M.O., Zicca A., Cadoni A., Merlo F., and Gogioso L. Effect of antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedichloroplatinum(II). Toxicol. Appl. Pharmacol. 140 (1996) 370-377
19. Viale M., Vannozzi M.O., Pastrone I., Mariggiò M.A., Zicca A., Cadoni A., Cafaggi S., Tolino G., Lunardi G., Civalleri D., Lindup W.E., and Esposito M. Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role?. J. Pharmacol. Exp. Ther. 293 (2000) 829-836
20. Zicca A., Cafaggi S., Mariggiò M.A., Vannozzi M.O., Ottone M., Bocchini V., Caviglioli G., and Viale M. Reduction of cisplatin hepatotoxicity by procainamide hydrochloride in rats. Eur. J. Pharmacol. 442 (2002) 265-272
21. Ottone M., Cafaggi S., Chiavarina B., Mariggiò M.A., and Viale M. Potentiation of cisplatin (DDP)-induced apoptosis by procainamide hydrochloride (PdHCl) in murine P388 leukemia cells in vitro. Tumori 4 Suppl. 2 (2005) 180
22. Wilson J.G. Methods for administering agents and detecting malformations in experimental animals. In: Wilson J.G., and Warkany J. (Eds). Teratology: Principles and Techniques (1965), University of Chicago Press, Chicago 262-277
23. Staples R.E., and Schnell V.L. Refinements in rapid clearing technic in the KOH-Alizarin Red S method for foetal bone. Stain. Technol. 39 (1964) 61-64
24. Wise L.D., Beck S.L., Beltrame D., Beyer B.K., Chahoud I., Clark R.L., Clark R., Druga A.M., Feuston M.H., Guittin P., Henwood S.M., Kimmel C.A., Lindstrom P., Palmer A.K., Petrere J.A., Solomon H.M., Yasuda M., and York R.G. Terminology of developmental abnormalities in common laboratory mammals (Version 1). Teratology 55 (1997) 249-292
25. Aliverti V., Bonanomi L., Giavini E., Leone V.G., and Mariani L. The extent of fetal ossification as an index of delayed development in teratogenic studies on the rat. Teratology 20 (1979) 237-242
26. Vannozzi M.O., Ottone M., Mariggiò M.A., Cafaggi S., Parodi B., Cilli M., Lindup W.E., and Viale M. Pharmacokinetic and pharmacodynamic analysis of platinum after combined treatment of cisplatin and procainamide hydrochloride in mice bearing P388 leukemia. Anticancer Res. 23 (2003) 1509-1516
27. Mollman J.E., Glover D.J., Hogan W.M., and Furman R.E. Cisplatin neuropathy risk factors, prognosis and protection by WR-2721. Cancer 61 (1988) 2192-2195
28. Hartmann J.T., Kollmannsberger C., Kanz L., and Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int. J. Cancer 83 (1999) 866-869
29. Arany I., and Safirstein R.L. Cisplatin nephrotoxicity. Sem. Oncol. 23 (2003) 460-464
30. Köpf-Maier P. Stage of pregnancy-dependent transplacental passage of 195Pt after cis-platinum treatment. Eur. Cancer Clin. Oncol. 19 (1983) 533-536
31. Fujii T., and Nakatsuka T. Potentiating effects of caffeine on teratogenicity of alkylating agents in mice. Teratology 28 (1983) 29-33
32. Bishop J.B., and Wassom J.S. Toxicological review of busulfan (Myleran). Mutat. Res. 168 (1986) 15-45
33. Aggarwal S.K., Keller K.A., and Bajt M.L. Embryotoxicity of cisplatin in rats and mice: possible factors responsible. Proceedings of the Fourth International Platinum Symposium. Burlington/Vermont (1983) 158
34. Esposito M., Viale M., Vannozzi M.O., and De Cian F. Modulation of the therapeutic efficacy of cisplatin in rats using procainamide. Tumori 81 Suppl. 4 (1995) 135
35. Cafaggi S., Esposito M., Parodi B., Vannozzi M.O., Viale M., Pellecchia C., Fulco R.A., Merlo F., Zicca A., Cadoni A., and Bignardi G. Synthesis and antitumour activity of a new cis-diammineplatinum(II) complex containing procaine hydrochloride. Anticancer Res. 12 (1992) 2285-2292
36. Joglar J.A., and Page R.L. Treatment of cardiac arrhythmias during pregnancy: safety considerations. Drug Safety 20 (1999) 85-94
37. Rotmensch H.H., Rotmensch S., and Elkayam U. Management of cardiac arrhytmias during pregnancy. Current Concepts Drugs 33 (1987) 623-633
38. Gowda R.M., Khan I.A., Mehta N.J., Vasavada B.C., and Sacchi J. Cardiac arrhythmias in pregnancy: clinical and therapeutic considerations. Int. J. Cardiol. 88 (2003) 129-133
39. Leazer T.M., and Klaassen C.D. The presence of xenobiotic transporters in rat placenta. Drug Met. Disp. 31 (2003) 153-167
40. Ganapathy V., Prasad P.D., Ganapathy M.E., and Leibach F.H. Placental transporters relevant to drug distribution across the maternal-fetal interface. J. Pharmacol. Exp. Ther. 294 (2000) 413-420
41. Somoyi A., McLean A., and Heinzow B. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur. J. Clin. Pharmacol. 25 (1983) 339-345
42. 4]-chloride platinum (II) monohydrochloride monohydrate. Arch. Toxicol. 78 (2004) 584-588
43. Terashima M., Ikeda K., Takagane A., Sasaki N., Abe K., Araya M., Nishizuka S., Yonezawa H., Irinoda T., Nakaya T., Oyama K., and Saito K. Pharmacokinetic analysis of intra-peritoneal administration of cisplatin. Gan Kagaku Ryoko 24 (1997) 1859-1862
44. Casper E.S., Kelsen D.P., Alcock N.W., and Lewis Jr. J.L. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat. Rep. 67 (1983) 235-238